“1,000 conversations I’d rather have than that one:” A qualitative study of prescriber experiences with opioids and the impact of a prescription drug monitoring program

References

• Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(50–51):1445–52. doi:10.15585/mmwr.mm655051e1.
   PubMed Web of Science ®Google Scholar
• Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993–2009. PLoS One. 2013;8(2):e54496. doi:10.1371/journal.pone.0054496.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49. doi:10.15585/mmwr.rr6501e1.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Pham-Kanter G, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: Results from a survey of general internists. Subst Abus. 2016;37(4):635–41. doi:10.1080/08897077.2016.1187240.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Baggett MV, Pham-Kanter G, Campbell EG. Internal medicine residents’ training in substance use disorders: a survey of the quality of instruction and residents’ self-perceived preparedness to diagnose and treat addiction. Subst Abus. 2013;34(4):363–70. doi:10.1080/08897077.2013.797540.
   PubMed Web of Science ®Google Scholar
• Saitz R, Friedmann PD, Sullivan LM, Winter MR, Lloyd-Travaglini C, Moskowitz MA, Samet JH. Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives. J Gen Intern Med. 2002;17(5):373–6. doi:10.1046/j.1525-1497.2002.10520.x.
   PubMed Web of Science ®Google Scholar
• Bieber C, Müller KG, Blumenstiel K, et al. Long-term effects of a shared decision-making intervention on physician-patient interaction and outcome in fibromyalgia. A qualitative and quantitative 1 year follow-up of a randomized controlled trial. Patient Educ Couns. 2006;63(3):357–66. doi:10.1016/j.pec.2006.05.003.
   PubMed Web of Science ®Google Scholar
• Eggly S, Tzelepis A. Relational control in difficult physician-patient encounters: negotiating treatment for pain. J Health Commun. 2001;6(4):323–33. doi:10.1080/108107301317140814.
   PubMed Web of Science ®Google Scholar
• Matthias MS, Parpart AL, Nyland KA, et al. The patient-provider relationship in chronic pain care: providers’ perspectives. Pain Med. 2010;11(11):1688–97. doi:10.1111/j.1526-4637.2010.00980.x.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. JAMA. 2015;313(9):891–2. doi:10.1001/jama.2014.18514.
   PubMed Web of Science ®Google Scholar
• Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM. Abrupt decline in oxycodone-caused mortality after implementation of Florida’s Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015;150:63–8. doi:10.1016/j.drugalcdep.2015.02.010.
   PubMed Web of Science ®Google Scholar
• Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35(7):1324–32. doi:10.1377/hlthaff.2015.1496.
   PubMed Web of Science ®Google Scholar
• Li G, Brady JE, Lang BH, Giglio J, Wunsch H, DiMaggio C. Prescription drug monitoring and drug overdose mortality. Inj Epidemiol. 2014;1(1):9. doi:10.1186/2197-1714-1-9.
   PubMedGoogle Scholar
• Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747–54. doi:10.1111/j.1526-4637.2011.01062.x.
   PubMed Web of Science ®Google Scholar
• Weiner SG, Kobayashi K, Reynolds J, et al. Opioid Prescribing after Implementation of Single Click Access to a State Prescription Drug Monitoring Program Database in a Health System’s Electronic Health Record. Pain Med. 2021;22(10):2218–2223. doi:10.1093/pm/pnab051.
   PubMed Web of Science ®Google Scholar
• Moyo P, Simoni-Wastila L, Griffin BA, et al. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. Addiction. 2017;112(10):1784–96. doi:10.1111/add.13860.
   PubMed Web of Science ®Google Scholar
• Bao Y, Pan Y, Taylor A, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35(6):1045–51. doi:10.1377/hlthaff.2015.1673.
   PubMed Web of Science ®Google Scholar
• Wen H, Hockenberry JM, Jeng PJ, Bao Y. Prescription drug monitoring program mandates: impact on opioid prescribing and related hospital use. Health Aff (Millwood). 2019;38(9):1550–6. doi:10.1377/hlthaff.2019.00103.
   PubMed Web of Science ®Google Scholar
• Wilson MN, Hayden JA, Rhodes E, Robinson A, Asbridge M. Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: a systematic review. J Pain. 2019;20(12):1383–93. doi:10.1016/j.jpain.2019.04.007.
   PubMed Web of Science ®Google Scholar
• Lin H-C, Wang Z, Boyd C, Simoni-Wastila L, Buu A. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav. 2018;76:348–54. doi:10.1016/j.addbeh.2017.08.032.
   PubMed Web of Science ®Google Scholar
• Pomerleau AC, Nelson LS, Hoppe JA, Salzman M, Weiss PS, Perrone J. The impact of prescription drug monitoring programs and prescribing guidelines on emergency department opioid prescribing: a multi-center survey. Pain Med. 2017;18(5):889–97. doi:10.1093/pm/pnw032.
   PubMed Web of Science ®Google Scholar
• Rhodes E, Wilson M, Robinson A, Hayden JA, Asbridge M. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Serv Res. 2019;19(1):784. doi:10.1186/s12913-019-4642-8.
   PubMed Web of Science ®Google Scholar
• Lin DH, Lucas E, Murimi IB, et al. Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP). Addiction. 2017;112(2):311–9. doi:10.1111/add.13620.
   PubMed Web of Science ®Google Scholar
• Freeman PR, Curran GM, Drummond KL, et al. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: results from a multi-site qualitative study. Res Social Adm Pharm. 2019;15(6):754–60. doi:10.1016/j.sapharm.2018.09.007.
   PubMed Web of Science ®Google Scholar
• Hong M, Seymour S, Stopka TJ, et al. Nobody knows how youre supposed to interpret it: ‘end-user perspectives on prescription drug monitoring program in Massachusetts. J Addict Med. 2021. doi:10.1097/ADM.0000000000000901.
   PubMed Web of Science ®Google Scholar
• Radomski TR, Bixler FR, Zickmund SL, et al. Physicians’ perspectives regarding prescription drug monitoring program use within the department of veterans affairs: a multi-state qualitative study. J Gen Intern Med. 2018;33(8):1253–9. doi:10.1007/s11606-018-4374-1.
   PubMed Web of Science ®Google Scholar
• Strickler GK, Zhang K, Halpin JF, Bohnert ASB, Baldwin GT, Kreiner PW. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019;199:1–9. doi:10.1016/j.drugalcdep.2019.02.010.
   PubMed Web of Science ®Google Scholar
• Rutkow L, Smith KC, Lai AY, Vernick JS, Davis CS, Alexander GC. Prescription drug monitoring program design and function: a qualitative analysis. Drug Alcohol Depend. 2017;180:395–400. doi:10.1016/j.drugalcdep.2017.08.040.
   PubMed Web of Science ®Google Scholar
• Fulton-Kehoe D, Von Korff M, Mai J, et al. Surveillance of opioid prescribing as a public health intervention: Washington state bree collaborative opioid metrics. J Public Health Manag Pract. 2020;26(3):206–13. doi:10.1097/PHH.0000000000001067.
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Philpot LM, Clements CM, Lovely JK, Nicholson WT, Jenkins SM, Lamer TJ, Gazelka HM. Attitudes, beliefs, practices, and concerns among clinicians prescribing opioids in a large academic institution. Pain Med. 2018;19(9):1790–8. doi:10.1093/pm/pnx140.
   PubMed Web of Science ®Google Scholar
• Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360–3.
   PubMed Web of Science ®Google Scholar
• Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21(6):652–5. doi:10.1111/j.1525-1497.2006.00412.x.
   PubMed Web of Science ®Google Scholar
• Click IA, Basden JA, Bohannon JM, Anderson H, Tudiver F. Opioid prescribing in rural family practices: a qualitative study. Subst Use Misuse. 2018;53(4):533–40. doi:10.1080/10826084.2017.1342659.
   PubMed Web of Science ®Google Scholar
• Pugliese JA, Wintemute GJ, Henry SG. Psychosocial correlates of clinicians’ prescription drug monitoring program utilization. Am J Prev Med. 2018;54(5):e91–e98. doi:10.1016/j.amepre.2018.02.009.
   PubMed Web of Science ®Google Scholar
• Razouki Z, Khokhar BA, Philpot LM, Ebbert JO. Attributes, attitudes, and practices of clinicians concerned with opioid prescribing. Pain Med. 2019;20(10):1934–41. doi:10.1093/pm/pny204.
   PubMed Web of Science ®Google Scholar
• Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009;10(12):1187–204. doi:10.1016/j.jpain.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Burgess DJ, Phelan S, Workman M, et al. The effect of cognitive load and patient race on physicians’ decisions to prescribe opioids for chronic low back pain: a randomized trial. Pain Med. 2014;15(6):965–74. doi:10.1111/pme.12378.
   PubMed Web of Science ®Google Scholar
• Tait RC, Chibnall JT. Racial/ethnic disparities in the assessment and treatment of pain: psychosocial perspectives. Am Psychol. 2014;69(2):131–41. doi:10.1037/a0035204.
   PubMed Web of Science ®Google Scholar
• Hirsh AT, Hollingshead NA, Ashburn-Nardo L, Kroenke K. The interaction of patient race, provider bias, and clinical ambiguity on pain management decisions. J Pain. 2015;16(6):558–68. doi:10.1016/j.jpain.2015.03.003.
   PubMed Web of Science ®Google Scholar
• Sabin JA, Greenwald AG. The influence of implicit bias on treatment recommendations for 4 common pediatric conditions: pain, urinary tract infection, attention deficit hyperactivity disorder, and asthma. Am J Public Health. 2012;102(5):988–95. doi:10.2105/AJPH.2011.300621.
   PubMed Web of Science ®Google Scholar
• Clark MR, Hurley RW, Adams MCB. Re-assessing the validity of the opioid risk tool in a tertiary academic pain management center population. Pain Med. 2018;19(7):1382–95. doi:10.1093/pm/pnx332.
   PubMed Web of Science ®Google Scholar
• Witry MJ, St Marie BJ, Viyyuri BR, Windschitl PD. Factors influencing judgments to consult prescription monitoring programs: a factorial survey experiment. Pain Manag Nurs. 2020;21(1):48–56. doi:10.1016/j.pmn.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Blum CJ, Nelson LS, Hoffman RS. A survey of physicians’ perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP). J Subst Abuse Treat. 2016;70:35–43. doi:10.1016/j.jsat.2016.07.013.
   PubMed Web of Science ®Google Scholar
• Sun BC, Lupulescu-Mann N, Charlesworth CJ, et al. Variations in prescription drug monitoring program use by prescriber specialty. J Subst Abuse Treat. 2018;94:35–40. doi:10.1016/j.jsat.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Goodin AJ, Brown JD, Delcher C, et al. Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Res Social Adm Pharm. 2020;16(9):1306–8. doi:10.1016/j.sapharm.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Blevins CE, Rawat N, Stein MD. Gaps in the substance use disorder treatment referral process: provider perceptions. J Addict Med. 2018;12(4):273–7. doi:10.1097/ADM.0000000000000400.
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Lemon SC, Stein MD, D’Aunno TA. Community referral sources and entry of treatment-naive clients into outpatient addiction treatment. Am J Drug Alcohol Abuse. 2003;29(1):105–15. doi:10.1081/ada-120018841.
   PubMed Web of Science ®Google Scholar
• Klag S, O’Callaghan F, Creed P. The use of legal coercion in the treatment of substance abusers: an overview and critical analysis of thirty years of research. Subst Use Misuse. 2005;40(12):1777–95. doi:10.1080/10826080500260891.
   PubMed Web of Science ®Google Scholar
• Goodin A, Bae J, Delcher C, Brown J, Roussos-Ross D. Obstetrician-gynecologist perceptions and utilization of prescription drug monitoring programs: A survey study. Medicine. 2021;100(1):e24268. doi:10.1097/MD.0000000000024268.
   PubMed Web of Science ®Google Scholar